Tri Chemical Laboratories (4369) Q1 2027 earnings summary

Executive summary

• Net sales rose 14.0% year-over-year to ¥7,488 million for the three months ended April 30, 2026.

• Operating profit increased 20.8% year-over-year to ¥2,069 million.

• Profit attributable to owners of parent surged 53.6% year-over-year to ¥1,855 million.

• Comprehensive income more than doubled year-over-year, reaching ¥1,749 million.

Financial highlights

• Gross profit improved to ¥2,799 million from ¥2,485 million year-over-year.

• Ordinary profit jumped 51.5% year-over-year to ¥2,485 million.

• Basic earnings per share increased to ¥57.09 from ¥37.16 year-over-year.

• Equity-to-asset ratio stood at 77.9% as of April 30, 2026.

• Net cash provided by operating activities was ¥1,776 million, up from ¥688 million year-over-year.

Outlook and guidance

• Full-year net sales forecast at ¥27,000 million, up 1.7% year-over-year.

• Operating profit for the full year projected at ¥6,000 million, up 1.7% year-over-year.

• Profit attributable to owners of parent expected to reach ¥4,600 million, up 16.6% year-over-year.

• Annual dividend forecast maintained at ¥35.00 per share.